Нарушения на съня след ендокринна терапия при жени с рак на гърдата
Ключови думи :
карцином на млечна жлеза, нарушение на съня, качество на животАбстракт
Въведение: Ендокринната терапия е стандартно лечение при жени с карцином на млечна жлеза. Тя може да причини нарушения на съня, които повлияват нормалното функциониране на жените. Целта на настоящото проучване е да се анализират резултатите от въпросите, свързани с нарушенията на съня, и резултатите от скалите за физическо, ролево и емоционално функциониране при жени с карцином на гърда, провеждащи хормонална терапия. Материал и методи: Представени са резултатите на 210 жени. Използван е въпросник за демографски показатели и въпросник за качество на живот. За статистически анализ и обработка на данните са използвани Excel и SPSS програма v26. Резултати и обсъждане: Над 2/3 от анкетираните лица споделят за нарушения в съня – 72%. Между резултатите за проблемите със съня и физическата функция се открива умерена корелационна зависимост при (r = 0.358, p = 0.000), безсънието, лошото качество на съня се отразяват неблагоприятно на осъществяването на нормалните ежедневни дейности. Между нарушенията на съня и емоционалната функция се наблюдава умерена корелационна връзка при (r = 0.349, p = 0.000). Проблемите със съня са в умерена зависимост с ролевото функциониране (r = 0.343, p = 0.000). Заключение: Нарушението на съня е сериозно предизвикателство пред жените, които са подложени на хормонална терапия за рак на гърдата. Своевременната оценка на симптомите на безсъние е необходима, за да се разбере проблемът и да се приложи необходимата терапия.
Литература (библиография)
Howlader N, Noone A, Krapcho M et al. SEER cancer statistics review. 2019; 1975-2016.
Burstein HJ, Lacchetti C, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression J Clin Oncol, 2016; 34:1689-1701.
Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol, 2010; 11:1135-1141. doi:10.1016/S1470-2045(10)70257-6.
Curigliano G, Burstein HJ, Winer EP et al. De-escalating and escalating treatments for early-stage breast cancer: the st. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 Ann Oncol, 2017; 28:1700-1712, doi:10.1093/annonc/mdx308.
Mouridsen H, Giobbie A, Hurder A et al. Coates BIG 1-98 collaborative group, letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med, 2009; 361:766-776. doi:10.1056/NEJMoa0810818.
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update J Clin Oncol, 2019; 37:423-438. doi:10.1200/JCO.18.01160.
Yeo SM, Lim JY, Kim SW et al. Impact of Adjuvant Hormone Therapy on Sleep, Physical Activity, and Quality of Life in Premenopausal Breast Cancer: 12-Month Observational Study. J Breast Cancer. 2023; 26(2):93-104. doi: 10.4048/jbc.2023.26.e11.
Savard J, Ivers H, Morin CM et al. Cancer treatments and their side effects are associated with aggravation of insomnia: results of a longitudinal study Cancer, 2015, 121:1703-1711. doi:10.1002/cncr.29244.
Park JY, Lee SK, Bae SY et al. Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors J Korean Surg Soc, 2013, 85:205-211, doi:10.4174/jkss.2013.85.5.205.
Buijs C, de Vries EGE, Mourits MJE, Willemse PHB. The influence of endocrine treatments for breast cancer on health-related quality of life Cancer Treat Rev, 2008, 34:640-655. doi:10.1016/j.ctrv.2008.04.001.
Savard J, Davidson JR, Ivers H et al. The association between nocturnal hot flashes and sleep in breast cancer survivors J Pain Symptom Manag, 2004, 27:513-522. doi:10.1016/j.jpainsymman.2003.10.013.
Ganz PA, Cecchini RS, Julian TB et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Lancet, 2016, 387:857-865.
Kidwell KM, Harte SE, Hayes DF et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy Cancer, 2014, 120:2403-2411.
Henry NL, Azzouz F, Desta Z et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer, 2012.
Palesh O, Zeitzer JM, Conrad A et al. Vagal regulation, cortisol, and sleep disruption in women with metastatic breast cancer J Clin Sleep Med, 2008, 4:441-449.
Savard J, Morin CM. Insomnia in the context of cancer: a Review of a neglected problem J Clin Oncol, 2001, 19:895 908, doi:10.1200/JCO.2001.19.3.895.
Ancoli-Israel S. Sleep disturbances in cancer: a Review Sleep Med Res, 2015, 6. doi:10.17241/smr.2015.6.2.45.
Gabra, RH, Hashem, DF Sleep disorders and their relationship to other psychiatric disorders in women with breast cancer: a case-control study. Middle East Curr Psychiatry, 2021, 28(10). https://doi.org/10.1186/s43045-021-00090-z.
Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among US adults from 2002 to 2012 Sleep Med, 2015, 16:372-378.
Palesh O, Aldridge-Gerry A, Zeitzer JM et al. Actigraphy- measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep, 2014; 37(5):837e42
Harris B, Ross J, Sanchez-Reilly S. sleeping in the arms of cancer: a review of sleeping disorders among patients with cancer. Cancer J. 2014; 20(5):299-305.
Ancoli-Israel, Liu L, Marler M, Parker, BA et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer FACT-B: functional assessment of cancer therapy-breast. FOSQ: functional outcome of sleep questionnaire. MFSI-SF: multidimensional fatigue symptom inventory-short form. PSQI: pittsburgh sleep quality index Support Care Canc, 2006, 14:201-202.
Bower JE. Behavioral symptoms in breast cancer patients and survivors: fatigue, insomnia, depression, and cognitive disturbance Julienne J Clin Oncol, 2008, 26:768-777.
Hajj A, Hachem R, Khoury R et al. Clinical and Genetic Factors Associated With the Breast Cancer-Related Sleep Disorders: The “CAGE-Sleep” Study–A Cross-Sectional Study, Journal of Pain and Symptom Management, 2021;62(3):e46-e55, https://doi.org/10.1016/j.jpainsymman.2021.02.022.
Angford DJ, Lee K, Miaskowski C. Sleep disturbance interventions in oncology patients and family caregivers: a comprehensive review and meta-analysis. Sleep Med Rev 2012;16(5):397-414.
Win MR, Olmstead RE, Ganz PA, Haque R. Sleep disturbance, inflammation and depression risk in cancer survivors. Brain Behav Immun, 2013; 30(Suppl):S58-S67.
Cano A. Control emocional, estilo represivo de afrontamiento y cáncer: Ansiedad y cáncer. Psicooncología, 2005; 2(1):71-80.
Rand KL, Otte JL, Flockhart D et al. Modeling hot flushes and quality of life in breast cancer survivors, Climacteric, 2011; 14:1, 171-180.
Hayley MC, Williams LJ, Kennedy GA et al. Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep Med 15(3):348-354
Polo-Kantola P. Sleep problems in midlife and beyond. Maturitas. 2011;68(3):224-32.
Blumel JE, Cano A, Mezones-Holguin E et al. A multinational study of sleep disorders during female mid-life. Maturitas. 2012;72(4):359-66.
Pengo MF, Won CH, Bourjeily G. Sleep in women across the life span. CHEST. 2018;154(1):196-206.
Hachul De Campos H, Brando LC, D‘Almeida V et al. Sleep disturbances, oxidative stress and cardiovascular risk parameters in postmenopausal women complaining of insomnia. Climacteric. 2006;9(4):312-9.
Silva BH, Martinez D, Wender MCO. A randomized, controlled pilot trial of hormone therapy for menopausal insomnia. Arch Women’s Mental Health. 2011;14(6):505-8.
Whiteley J, Bushmakin A, Racketa J et al. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013;20(5):518-24.
Avis NE, Crawford SL, Greendale G et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Inter Med. 2015;175(4):531.
Holloway D. Managing the menopause: symptoms, consequences and treatment. Prim Health Care. 2016;26(7):40-9.
Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000.
Innominato PF, Levi FA, Bjarnason GA. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 2010;62:979-1001.
Palesh O, Peppone L, Innominato PF et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep 2012;4:151-162.
Palesh O, Aldridge-Gerry A, Zeitzer J et al. Actigraphy measured sleep disruption as a predictor of survival among women with advanced breast cancer [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 9532.
Lorizio W, Wu AH, Beattie MS et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat, 2012;132:1107-1118.
Savard J, Ivers H. The initiation of chemotherapy, but not radiation therapy, coincides with increased insomnia. Psychooncology, 2012;21:37-38.
Palesh O, Peppone L, Innominato PF et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep, 2012;4:151-162.
Vargas S, Wohlgemuth WK, Antoni MH et al. Sleep dysfunction and psychosocial adaptation among women undergoing treatment for non-metastatic breast cancer. Psychooncology, 2010;19:669-673.
Ancoli-Israel S, Liu L, Marler MR et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer, 2006;14:201-209.
Berger AM, Farr LA, Kuhn BR et al. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage, 2007;33:398-409.
Phillips KM, Jim HS, Donovan KA et al. Characteristics and correlates of sleep disturbances in cancer patients. Support Care Cancer 2012;20:357-365.
Berger AM, Kuhn BR, Farr LA et al. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol. 2009;27:6033-6040.
Grayson S, Sereika S, Harpel C et al. Factors associated with sleep disturbances in women undergoing treatment for early-stage breast cancer. Support Care Cancer, 2022; 30:157-166. https://doi.org/10.1007/s00520-021-06373-9.
Fortner BV, Stepanski EJ, Wang SC et al. Sleep and Quality of Life in Breast Cancer Patients, Journal of Pain and Symptom Management, 2002; 24(5):471-480, https://doi.org/10.1016/S0885-3924(02)00500-6.
Desai K, Mao JJ, Su I et al. Gehrman Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors Support Care Cancer, 2013; 21:43-51, doi:10.1007/s00520-012-1490-z.
Savard J, Liu L, Natarajan L et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy Sleep, 2009; 32:1155-1160, doi:10.1093/sleep/32.9.1155.
Mystakidou K, Parpa E, Tsilika E et al. Sleep quality in advanced cancer patients. J Psychosom Res, 2007; 62:527e533.
Файлове за сваляне
Публикуван
Брой
Раздел (Секция)
Лиценз
Публикация с Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Можете свободно да споделяте, копирате и разпространявате материала във всякакъв носител или формат при следните условия.
Списание Bulgarian Medical Journal (Български медицински журнал / Bulgarian Medical Journal) ISSN: 1313-1516 (Print)
